24 Jun InVitria
InVitria develops and commercializes high performance excipients, supplements, and media formulations that are used in cell therapy, CAR-T, gene therapy, cell-based vaccines, diagnostics, medical devices, biomanufacturing, and biopharmaceutical formulation. InVitria also offers custom media formulation services to cell therapy, vaccine, and gene therapy customers who seek blood-free and defined manufacturing systems. InVitria’s product portfolio includes recombinant albumin including optibumin, exbumin, and cellastim S as well as recombinant transferrin (Optiferrin), insulin, and transferrin supplements. InVitria’s blood-free and defined media products are optimized for specific cell types including: OptiVERO (VERO), OptiPEAK T Lymphocyte (CAR-T), and OptiPEAK HEK293t (HEK293t). www.invitria.com